Saudi Journal of Kidney Diseases and Transplantation

CASE REPORT
Year
: 2018  |  Volume : 29  |  Issue : 3  |  Page : 714--718

Should antiviral monotherapy with nucleotide analogs be the primary treatment option for focal segmental glomerulosclerosis-related nephrotic syndrome in chronic hepatitis B infection?


Muhammad M Javaid1, Priyanka Khatri2, Srinivas Subramanian1 
1 Division of Nephrology, University Medicine Cluster; Department of Medicine, Yong Loo Lin School of Medicine, National University Hospital, Singapore
2 Division of Nephrology, University Medicine Cluster, National University Hospital, Singapore

Correspondence Address:
Dr. Muhammad M Javaid
Division of Nephrology, University Medicine Cluster, National University Hospital, 119228
Singapore

Renal involvement is the most common extrahepatic manifestation of chronic hepatitis B virus (HBV) infection. While membranous nephropathy is the most frequent, the association with focal segmental glomerulosclerosis (FSGS) is not as strong, and only a few cases have been described in the literature. In particular, the tip variant FSGS is extremely rare and to our knowledge has not previously been described in association with chronic HBV infection. The management of such cases can be challenging. Immunosuppression may lead to enhanced viral replication and flare-up of the hepatic disease. Antiviral treatment has been reported to induce remission in hepatitis B-associated glomerulonephritis in a few cases. However, their use is primarily restricted to the treatment of associated liver disease, and the current guidelines do not provide specific recommendations on HBV-mediated kidney disease in the absence of hepatic involvement. We describe a case of nephrotic syndrome due to secondary tip variant FSGS in a patient with chronic HBV infection who went into complete remission with antiviral therapy alone and present an argument for the use of oral antiviral agents as the primary treatment option for FSGS-related nephrotic syndrome in chronic HBV-infected patients without progressive liver disease.


How to cite this article:
Javaid MM, Khatri P, Subramanian S. Should antiviral monotherapy with nucleotide analogs be the primary treatment option for focal segmental glomerulosclerosis-related nephrotic syndrome in chronic hepatitis B infection?.Saudi J Kidney Dis Transpl 2018;29:714-718


How to cite this URL:
Javaid MM, Khatri P, Subramanian S. Should antiviral monotherapy with nucleotide analogs be the primary treatment option for focal segmental glomerulosclerosis-related nephrotic syndrome in chronic hepatitis B infection?. Saudi J Kidney Dis Transpl [serial online] 2018 [cited 2022 Jun 25 ];29:714-718
Available from: https://www.sjkdt.org/article.asp?issn=1319-2442;year=2018;volume=29;issue=3;spage=714;epage=718;aulast=Javaid;type=0